BioUtah News
-
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter…
-
Bloom Surgical: 2025 Year In Review
2025 marked a year of significant progress of reached milestones and successes for Bloom Surgical
-
Adam Barker, PhD, Named President and Chief Operations Officer of ARUP Reference Business Unit
A microbiologist, Adam Barker, PhD, was ARUP’s chief scientific officer and director of Research and Development before being…
-
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.
-
Merit Medical’s Fred Lampropoulos Honored by Nasdaq
Merit Medical’s Fred Lampropoulos Honored by Nasdaq
-
Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million
Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million
-
Freyya Recognized at Transatlantic Angel Competition (TAAC8)
Freyya Recognized at Transatlantic Angel Competition (TAAC8)
-
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
-
Owlet Announces New DME Partnership With 1 Natural Way to Expand Insurance-Supported Access to BabySat® Infant Pulse Oximeter
Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in…
-
CancerVax Reports Nanoparticle Component Success in Preparation for Animal Studies
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside…
-
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
-
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
